Abstract
Background
Nitric oxide (NO) is a neurotransmitter that may be related to major depressive disorder (MDD) because the selective neuronal NO synthase (NOS) inhibitor, 7-nitroindazole, induces a dose-dependent antidepressant-like effect. NO modulates major neurotransmitters involved in the neurobiology of MDD, such as norepinephrine, serotonin, dopamine, and glutamate. In this study, we investigated the effects of antidepressants as NO modulators in acute and sub-chronic treatments.
Methods
Rats were injected with the SSRI paroxetine (PAR, 10 mg/kg), the SNRI milnacipran (MIL, 30 mg/kg), or the NaSSA mirtazapine (MIR, 10 mg/kg) for acute (1 h) or sub-chronic (3 weeks) treatment prior to analysis of nine brain regions (frontal cortex, temporal cortex, striatum, thalamus, hippocampus, midbrain, pons, cerebellum, and olfactory bulb). The mRNA expression levels of three NOS subtypes (neuronal: nNOS, inducible: iNOS, and endothelial: eNOS) were analyzed using real-time PCR with Taqman probes.
Results
Acute MIR treatment significantly increased nNOS mRNA expression in the hippocampus, midbrain, cerebellum and olfactory bulb, and iNOS mRNA expression in the frontal cortex and midbrain. Acute PAR and MIR treatments significantly increased eNOS mRNA expression in most brain regions. Conversely, sub-chronic treatment with all types of antidepressants resulted in significant decreases of eNOS mRNA expression in most brain regions.
Conclusions
Sub-chronic treatment with the three types of antidepressants consistently decreased eNOS mRNA expression levels in the rat brain. These effects may be associated with the involvement of the NO system in the mechanism of action of antidepressants.
Similar content being viewed by others
References
Andrews PW, Bharwani A, Lee KR, Fox M, Thomson JA Jr (2015) Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response. Neurosci Biobehav Rev 51:164–188. doi:10.1016/j.neubiorev.2015.01.018
Berendsen HH, Broekkamp CL (1997) Indirect in vivo 5-HT1A-agonistic effects of the new antidepressant mirtazapine. Psychopharmacology 133(3):275–282
Bernstein HG, Heinemann A, Krell D, Mawrin C, Bielau H, Danos P, Diekmann S, Keilhoff G, Bogerts B, Baumann B (2002) Further immunohistochemical evidence for impaired NO signaling in the hypothalamus of depressed patients. Ann N Y Acad Sci 973:91–93
Bredt DS, Snyder SH (1994) Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem 63:175–195
Blendy JA (2006) The role of CREB in depression and antidepressant treatment. Biol Psychiatry 59(12):1144–1150
Chopra K, Kumar B, Kuhad A (2011) Pathobiological targets of depression. Expert Opin Ther Targets 15:379–400
Chrapko WE, Jurasz P, Radomski MW, Lara N, Archer SL, Le Mellédo JM (2004) Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol Psychiatry 56(2):129–134
Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373(9665):746–758. doi:10.1016/S0140-6736(09)60046-5
Croom KF, Perry CM, Plosker GL (2009) Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs 23(5):427–452. doi:10.2165/00023210-200923050-00006
Di Rosso ME, Palumbo ML, Genaro AM (2015) Immunomodulatory effects of fluoxetine: a new potential pharmacological action for a classic antidepressant drug? Pharmacol Res in press
Ferreira FR, Oliveira AM, Dinarte AR, Pinheiro DG, Greene LJ, Silva WA Jr, Joca SR, Guimarães FS (2012) Changes in hippocampal gene expression by 7-nitroindazole in rats submitted to forced swimming stress. Genes Brain Behav 11(3):303–313. doi:10.1111/j.1601-183X.2011.00757.x
Funaki K, Nakajima S, Suzuki T, Mimura M, Uchida H (2016) Early improvements in individual symptoms to predict later remission in major depressive disorder treated with mirtazapine. J Clin Pharmacol in press
Glover ME, Pugh PC, Jackson NL, Cohen JL, Fant AD, Akil H, Clinton SM (2015) Early-life exposure to the SSRI paroxetine exacerbates depression-like behavior in anxiety/depression-prone rats. Neuroscience 284:775–797. doi:10.1016/j.neuroscience.2014.10.044
Glowinski J, Iversen LL (1996) Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J Neurochem 13(8):655–669
Glusa E, Pertz HH (2000) Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors. Br J Pharmacol 130(3):692–698
Huang X, Mao YS, Li C, Wang H, Ji JL (2014) Venlafaxine inhibits apoptosis of hippocampal neurons by up-regulating brain-derived neurotrophic factor in a rat depression model. Int J Clin Exp Pathol 7(8):4577–4586
Kadioglu M, Muci E, Ozyavuz R, Yaris E, Kesim M, Kalyoncu NI (2010) Paroxetine inhibited the relaxations induced by EFS in mice corpus cavernosum: is it a NOS inhibition? Fundam Clin Pharmacol 24(1):55–61. doi:10.1111/j.1472-8206.2009.00742.x
Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458. doi:10.1038/bmt.2012.244
Karolewicz B, Szebeni K, Stockmeier CA, Konick L, Overholser JC, Jurjus G, Roth BL, Ordway GA (2004) Low nNOS protein in the locus coeruleus in major depression. J Neurochem 91(5):1057–1066
Koprowski H, Zheng YM, Heber-Katz E, Fraser N, Rorke L, Fu ZF, Hanlon C, Dietzschold B (1993) In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases. Proc Natl Acad Sci U S A 90(7):3024–3027
Lee BH, Lee SW, Yoon D, Lee HJ, Yang JC, Shim SH, Kim DH, Ryu SH, Han C, Kim YK (2006) Increased plasma nitric oxide metabolites in suicide attempters. Neuropsychobiology 53(3):127–132
Naegeli KJ, O'Connor JA, Banerjee P, Morilak DA (2013) Effects of milnacipran on cognitive flexibility following chronic stress in rats. Eur J Pharmacol 703(1–3):62–66. doi:10.1016/j.ejphar.2013.02.006
Nakayama K, Sakurai T, Katsu H (2004) Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Brain Res Bull 63(3):237–241
National Research Council (US) Committee on Guidelines for the Use of Animals in Neuroscience and Behavioral Research (2003) National Academies Press, Washington, US
Oliveira RM, Guimarães FS, Deakin JF (2008) Expression of neuronal nitric oxide synthase in the hippocampal formation in affective disorders. Braz J Med Biol Res 41(4):333–341
Quitkin FM, Rabkin JG, Ross D, Stewart JW (1984) Identification of true drug response to antidepressants. Use of pattern analysis. Arch Gen Psychiatry 41(8):782–786
Quitkin FM, Rabkin JD, Markowitz JM, Stewart JW, McGrath PJ, Harrison W (1987) Use of pattern analysis to identify true drug response. A replication. Arch Gen Psychiatry 44(3):259–264
Selley ML (2004) Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression. J Affect Disord 80(2–3):249–256
Sevgi S, Ozek M, Eroglu L (2006) L-NAME prevents anxiety-like and depression-like behavior in rats exposed to restraint stress. Methods Find Exp Clin Pharmacol 28(2):95–99
Spiacci A Jr, Kanamaru F, Guimarães FS, Oliveira RM (2008) Nitric oxide-mediated anxiolytic-like and antidepressant-like effects in animal models of anxiety and depression. Pharmacol Biochem Behav 88(3):247–255
Stahl SM (2013) Stahl’s essential psychopharmacology: neuroscientific basis and practical application, 4th edn. Cambridge University Press, Cambridge
Talarowska M, Gałecki P, Maes M, Orzechowska A, Chamielec M, Bartosz G, Kowalczyk E (2012) Nitric oxide plasma concentration associated with cognitive impairment in patients with recurrent depressive disorder. Neurosci Lett 510(2):127–131. doi:10.1016/j.neulet.2012.01.018
Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, Furukawa TA (2011) Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev 12:CD006528. doi:10.1002/14651858.CD006528.pub2
Xing G, Chavko M, Zhang LX, Yang S, Post RM (2002) Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression. Schizophr Res 58(1):21–30
Yamamura S, Abe M, Nakagawa M, Ochi S, Ueno S, Okada M (2011) Different actions for acute and chronic administration of mirtazapine on serotonergic transmission associated with raphe nuclei and their innervation cortical regions. Neuropharmacology 60(4):550–560. doi:10.1016/j.neuropharm.2010.12.025
Yoshino Y, Ochi S, Yamazaki K, Nakata S, Abe M, Mori Y, Ueno S (2015) Antidepressant action via the nitric oxide system: a pilot study in an acute depressive model induced by arginin. Neurosci Lett 599:69–74. doi:10.1016/j.neulet.2015.05.043
Yildiz F, Erden BF, Ulak G, Utkan T, Gacar N (2000) Antidepressant-like effect of 7-nitroindazole in the forced swimming test in rats. Psychopharmacology 149(1):41–44
Acknowledgements
We wish to thank Ms. Chiemi Onishi for her technical assistance. This work was partially supported by a Health and Labor Science Research Grant from the Japanese Ministry of Health, Labour and Welfare, and a Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yoshino, Y., Ochi, S., Yamazaki, K. et al. Endothelial nitric oxide synthase in rat brain is downregulated by sub-chronic antidepressant treatment. Psychopharmacology 234, 1663–1669 (2017). https://doi.org/10.1007/s00213-017-4567-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-017-4567-z